{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T20:02:12Z","timestamp":1785182532337,"version":"3.55.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["813528"],"award-info":[{"award-number":["813528"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.nucmedbio.2024.108969","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T20:26:51Z","timestamp":1731443211000},"page":"108969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["New prospects for 89Zr-immuno-PET in brain applications \u2013 Alpha-synucleinopathies"],"prefix":"10.1016","volume":"140-141","author":[{"given":"Thomas E.","family":"Wuensche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro M.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert D.","family":"Windhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaare","family":"Bjerregaard-Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Sotty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Kallunki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benny","family":"Bang-Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guus A.M.S.","family":"van Dongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wissam","family":"Beaino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle J.","family":"Vugts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2024.108969_bb0005","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.7150\/thno.73509","article-title":"Advancing 89Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody \u2013 the choice of chelator is essential","volume":"12","author":"Wuensche","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0010","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1007\/s00259-023-06109-3","article-title":"Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-\u00df monoclonal antibody","author":"Stergiou","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0015","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s13311-022-01283-y","article-title":"A brain-targeting bispecific-multivalent antibody clears soluble amyloid-beta aggregates in Alzheimer\u2019s disease mice","volume":"19","author":"Rofo","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13195-018-0377-8","article-title":"Efficient clearance of A\u03b2 protofibrils in A\u03b2PP-transgenic mice treated with a brain-penetrating bifunctional antibody","volume":"10","author":"Syv\u00e4nen","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5582\/bst.2023.01288","article-title":"Monoclonal antibody therapy for Alzheimer\u2019s disease focusing on intracerebral targets","volume":"18","author":"Gu","year":"2024","journal-title":"Biosci Trends"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0030","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3390\/pharmaceutics14071412","article-title":"Reduction of \u03b1SYN pathology in a mouse model of PD using a brain-penetrating bispecific antibody","volume":"14","author":"Roshanbin","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0035","first-page":"14","article-title":"Alpha-Synuclein PET tracer development-an overview about current efforts","author":"Korat","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0040","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1016\/j.cell.2023.06.004","article-title":"Development of an \u03b1-synuclein positron emission tomography tracer for imaging synucleinopathies","volume":"186","author":"Xiang","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0045","first-page":"14","article-title":"The \u03b1-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases","author":"Smith","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0050","first-page":"208","article-title":"In vivo imaging of alpha-synuclein with antibody-based PET","author":"Roshanbin","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aay1359","article-title":"Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys","volume":"12","author":"Kariolis","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0060","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/(SICI)1096-9861(19961125)375:4<675::AID-CNE8>3.0.CO;2-Z","article-title":"Immunohistochemical localization of intraneuronal transferrin receptor immunoreactivity in the adult mouse central nervous system","volume":"375","author":"Moos","year":"1996","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0065","series-title":"IEEE nuclear science symposium conference record, 2005","first-page":"1624","article-title":"High resolution PET imaging characteristics of \/sup68\/Ga, \/sup124\/I and \/sup 89\/Zr Compared to \/sup 18\/F","volume":"vol. 3","author":"de Jong","year":"2005"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0070","first-page":"655","article-title":"Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET","volume":"18","author":"Verel","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0075","doi-asserted-by":"crossref","first-page":"13482","DOI":"10.1074\/jbc.M117.780296","article-title":"Selective imaging of internalized proteopathic-synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies","volume":"292","author":"Karpowicz","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0080","doi-asserted-by":"crossref","DOI":"10.1007\/s11307-024-01931-z","article-title":"Investigation of the impact of the H310A FcRn region mutation on 89Zr-immuno-PET brain Imaging with a BBB-shuttle anti-amyloid beta antibody","author":"Wuensche","year":"2024","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0085","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.7150\/thno.73509","article-title":"Advancing 89Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody \u2013 the choice of chelator is essential","volume":"12","author":"Wuensche","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0090","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1007\/s00259-023-06109-3","article-title":"Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-\u00df monoclonal antibody","volume":"50","author":"Stergiou","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5582\/bst.2023.01288","article-title":"Monoclonal antibody therapy for Alzheimer\u2019s disease focusing on intracerebral targets","volume":"18","author":"Gu","year":"2024","journal-title":"Biosci Trends"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0100","doi-asserted-by":"crossref","first-page":"308","DOI":"10.7150\/thno.17155","article-title":"Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor","volume":"7","author":"Hultqvist","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0105","first-page":"15","article-title":"Antibody-based in vivo Imaging of central nervous system targets\u2014evaluation of a pretargeting approach utilizing a TCO-conjugated brain shuttle antibody and radiolabeled tetrazines","author":"Bredack","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0110","first-page":"15","article-title":"Delivery of the Brainshuttle\u2122 amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans","author":"Grimm","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40035-020-00214-1","article-title":"SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-\u03b2 antibody in a mouse model of Alzheimer\u2019s disease","volume":"9","author":"Gustavsson","year":"2020","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13195-018-0377-8","article-title":"Efficient clearance of A\u03b2 protofibrils in A\u03b2PP-transgenic mice treated with a brain-penetrating bifunctional antibody","volume":"10","author":"Syv\u00e4nen","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0125","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2967\/jnumed.121.262083","article-title":"11C-PiB and 124I-antibody PET provide differing estimates of brain amyloid-b after therapeutic intervention","volume":"63","author":"Meier","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0130","first-page":"208","article-title":"In vivo imaging of alpha-synuclein with antibody-based PET","author":"Roshanbin","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0135","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.neuroimage.2018.10.011","article-title":"High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain","volume":"184","author":"Fang","year":"2019","journal-title":"Neuroimage"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12987-021-00257-0","article-title":"Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size","volume":"18","author":"Faresj\u00f6","year":"2021","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0145","doi-asserted-by":"crossref","first-page":"18675","DOI":"10.1074\/jbc.M116.734707","article-title":"The effect of fragmented pathogenic \u03b1-synuclein seeds on prion-like propagation","volume":"291","author":"Tarutani","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0150","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3233\/JPD-171248","article-title":"Best practices for generating and using alpha-synuclein pre-formed fibrils to model Parkinson\u2019s disease in rodents","volume":"8","author":"Polinski","year":"2018","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0155","doi-asserted-by":"crossref","first-page":"12161","DOI":"10.1128\/JVI.75.24.12161-12168.2001","article-title":"Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1","volume":"75","author":"Hezareh","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0160","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4161\/cbt.26106","article-title":"The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity","volume":"14","author":"Lin","year":"2013","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0165","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.mcn.2008.08.001","article-title":"Lrrk2 and \u03b1-synuclein are co-regulated in rodent striatum","volume":"39","author":"Westerlund","year":"2008","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-021-00471-2","article-title":"Microglial inclusions and neurofilament light chain release follow neuronal \u03b1-synuclein lesions in long-term brain slice cultures","volume":"16","author":"Barth","year":"2021","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0175","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s00259-020-05002-7","article-title":"Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET","volume":"48","author":"Chomet","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0180","series-title":"Engineered antibodies: new possibilities for brain PET?","first-page":"2848","volume":"vol. 11","author":"Sehlin","year":"2019"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0185","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.neuroimage.2018.10.011","article-title":"High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain","volume":"184","author":"Fang","year":"2019","journal-title":"Neuroimage"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0190","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.neuroimage.2017.01.004","article-title":"A bispecific Tribody PET radioligand for visualization of amyloid-beta protofibrils \u2013 a new concept for neuroimaging","volume":"148","author":"Syv\u00e4nen","year":"2017","journal-title":"Neuroimage"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms10759","article-title":"Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer\u2019s disease","volume":"7","author":"Sehlin","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-17358-2","article-title":"Pharmacokinetics, biodistribution and brain retention of a bispecific antibody-based PET radioligand for imaging of amyloid-\u03b2","volume":"7","author":"Sehlin","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0205","first-page":"208","article-title":"In vivo imaging of alpha-synuclein with antibody-based PET","author":"Roshanbin","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0210","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.freeradbiomed.2018.06.037","article-title":"Transferrin and transferrin receptors update","volume":"133","author":"Kawabata","year":"2019","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0215","doi-asserted-by":"crossref","first-page":"308","DOI":"10.7150\/thno.17155","article-title":"Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor","volume":"7","author":"Hultqvist","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0220","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/jnc.15768","article-title":"A single-chain fragment constant design enables easy production of a monovalent blood\u2013brain barrier transporter and provides an improved brain uptake at elevated doses","volume":"165","author":"Morrison","year":"2023","journal-title":"J Neurochem"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0225","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2339337","article-title":"Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-\u03b2 antibody","volume":"16","author":"Schlein","year":"2024","journal-title":"MAbs"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0230","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood\u2013brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0235","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0169-328X(99)00226-0","article-title":"Iron-independent neuronal expression of transferrin receptor mRNA in the rat","volume":"72","author":"Moos","year":"1999","journal-title":"Mol Brain Res"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0240","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/(SICI)1096-9861(19980831)398:3<420::AID-CNE8>3.0.CO;2-1","article-title":"Expression of the neuronal transferrin receptor is age dependent and susceptible to iron deficiency","volume":"398","author":"Moos","year":"1998","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/sciadv.add1101","article-title":"Brain injury accelerates the onset of a reversible age-related microglial phenotype associated with inflammatory neurodegeneration","volume":"9","author":"Ritzel","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0250","first-page":"1","article-title":"Blocking autofluorescence in brain tissues affected by ischemic stroke, hemorrhagic stroke, or traumatic brain injury","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0255","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0260","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.neuroimage.2009.03.083","article-title":"Measurement of cerebral blood volume in mouse brain regions using micro-computed tomography","volume":"47","author":"Chugh","year":"2009","journal-title":"Neuroimage"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/sciadv.adf3775","article-title":"Single-domain antibody-based noninvasive in vivo imaging of \u03b1-synuclein or tau pathology","volume":"9","author":"Jiang","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0270","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0896-6273(02)00682-7","article-title":"Neuronal \u03b1-synucleinopathy with severe movement disorder in mice expressing A53T human \u03b1-synuclein","volume":"34","author":"Giasson","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.nucmedbio.2024.108969_bb0275","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"\u201cKnobs-into-holes\u201d engineering of antibody C(H)3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805124000957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805124000957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T16:32:01Z","timestamp":1741710721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805124000957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":55,"alternative-id":["S0969805124000957"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108969","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New prospects for 89Zr-immuno-PET in brain applications \u2013 Alpha-synucleinopathies","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108969"}}